Harvard Bioscience Reports 6.3% Revenue Decline in Q3 2025 Amid Financial Challenges

Harvard Bioscience, Inc. reported a decline in financial performance for the third quarter of 2025, with revenues of $20.6 million, down 6.3% from $22.0 million in the same period last year. For the nine months ended September 30, 2025, total revenues decreased by 9.7% to $62.8 million compared to $69.6 million in 2024. The decrease in revenue was attributed to a softening demand from academic research institutions and contract research organizations (CROs), compounded by the impact of reciprocal tariffs affecting international trade.

The company's gross profit for the third quarter was $12.0 million, a decrease of 5.8% from $12.8 million in the prior year, while the gross margin slightly improved to 58.4% from 58.1%. Operating expenses also saw a reduction, with sales and marketing expenses down 16.4% to $4.6 million, and general and administrative expenses decreasing by 17.2% to $4.2 million. However, the company recorded a significant goodwill impairment charge of $48.0 million for the nine-month period, reflecting a decline in its stock price and operational challenges.

In terms of operational metrics, Harvard Bioscience's cash and cash equivalents increased to $6.8 million as of September 30, 2025, compared to $4.1 million at the end of 2024. The company reported a net loss of $1.2 million for the third quarter, an improvement from a loss of $4.8 million in the same quarter of 2024. For the nine months, the net loss was $53.9 million, compared to a loss of $12.4 million in the previous year. The company’s employee headcount and customer engagement metrics were not disclosed in the filing.

Strategically, Harvard Bioscience is navigating significant financial challenges, including compliance issues with its Credit Agreement. The company entered into an amendment in August 2025 to address defaults related to refinancing milestones and financial covenants. The amendment allows the company to avoid immediate repayment of its $34 million debt but requires it to achieve refinancing or repayment by December 5, 2025. The company is actively exploring alternative sources of capital to meet its obligations, although there is substantial doubt about its ability to continue as a going concern without securing additional funding.

Looking ahead, Harvard Bioscience's management has indicated that the ongoing economic uncertainties and the impact of tariffs may continue to affect revenue and operational performance. The company is focused on restructuring efforts and improving its financial position, but the success of these initiatives remains uncertain. The management's outlook emphasizes the need for strategic adjustments to navigate the current market conditions effectively.